​What is Retatrutide?

​Retatrutide (LY-3437943) is an experimental medication currently under investigation by Eli Lilly for the treatment of obesity, weight management, and type 2 diabetes. Unlike current weight-loss therapies that target one or two hormonal pathways, Retatrutide is classified as a triple hormone receptor agonist.

The Triple-Agonist Mechanism: How It Works

​Retatrutide is designed to mimic three distinct gut hormones. By activating these three receptors simultaneously, the medication aims to create a more comprehensive metabolic response than previous-generation incretin therapies.

• ​GLP-1 (Glucagon-like peptide-1): Primarily aids in appetite suppression and slows gastric emptying to increase satiety.

• ​**GIP (Glucose-dependent insulinotropic polypeptide): Supports insulin sensitivity and lipid metabolism, which can improve overall metabolic balance.

• ​Glucagon Receptor: Unlike medications targeting only GLP-1 and GIP, Retatrutide also engages the glucagon receptor, which is theorized to increase the body’s energy expenditure (fat burning).